Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Genitourinary 1

Conditions

Prostatic Neoplasms 3Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Endometrial Adenocarcinoma 1Carcinoma, Transitional Cell 1

Interventions

pembrolizumab 31Nivolumab 12Cyclophosphamide 10fludarabine 9aldesleukin 8atezolizumab 7durvalumab 6Magnetic Resonance Spectroscopy 6Trastuzumab 5Specimen Handling 5Paclitaxel 5Ipilimumab 5Docetaxel 5Biopsy 5fludarabine phosphate 4Radiotherapy 4Interleukin-2 4Gene Expression Profiling 4Carboplatin 4tisotumab vedotin 3cemiplimab 3aflibercept 3Polymerase Chain Reaction 3Immunoglobulin G 3Early Intervention, Educational 3Cisplatin 3Bevacizumab 3tremelimumab 2tislelizumab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × nintedanib × Genitourinary × Clear all
NCT02835833 2018-07-10

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

University of Alabama at Birmingham

Phase 1 Completed
21 enrolled
GenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡